Live Chat

ट्रेड Vir Biotechnology VIR

बेचें
 खरीदें

VirBiotechnology लाइव चार्ट

5m 15m 30m 1h 4h 1d 1w

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

नवीनतम समाचार

Dyogenes Diniz 2025 Jan 04, 22:00

Week ahead: Manufacturing and Services PMI, US Unemployment and the last data before Trump takes office.

Cryptocurrencies USD
Frances Wang 2025 Jan 02, 16:00

AVAV stock rise: why AeroVironment stock surges today?

Stocks
Frances Wang 2025 Jan 02, 16:00

N2OFF Stock Surges After Key Approval for Solar PV Project in Melz

Stocks
Frances Wang 2025 Jan 01, 16:00

AMZN Stock price prediction: Will Amazon Stock Hits New Highs in 2025?

Stocks
Frances Wang 2024 Dec 30, 16:00

NXU stock news today: What is happening with NXU?

Stocks
Frances Wang 2024 Dec 30, 16:00

BigBear.ai Stock Is Skyrocketing: what to know about BBAI?

Stocks
Frances Wang 2024 Dec 29, 16:00

Stock market today: Most Asian stocks fell after US equities declined

Stocks
Frances Wang 2024 Dec 29, 16:00

MicroStrategy joins Nasdaq-100 index: MSTR stock performance analysis 2024

Cryptocurrencies Stocks

जानकारी

स्प्रेड

0.05

स्प्रेड (%)

0.6702 %

लीवरेज

1:5

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

सोमवार

14:31 - 20:59

मंगवार

14:31-20:59

बुधवार

14:31-20:59

गुरुवार

14:31-20:59

शुक्रवार

14:31-20:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

1032899968

बकाया शेयर

137720000

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

पूर्व-लाभांश तिथि

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-3.93

इस उपकरण के बारे में अधिक जानें

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें
view_all_instruments
Trustpilot
Live Chat